BACKGROUND: Physiologic processes during ageing leading to multi-morbidity and diseases that increase risk of premature death may be influenced by ageing-associated changes in endogenous hormone production. OBJECTIVE: To evaluate the decline in sex steroid hormone levels across age and estimate the number of US men 40+ years old who may have low hormone levels. DESIGN: We measured serum testosterone, oestradiol and sex hormone binding globulin by immunoassay in 1351 men 20+ years old in Third National Health and Nutrition Examination Survey. We estimated free hormones by mass action. RESULTS: Free testosterone declined most rapidly with age (a 2% decline in geometric mean concentration occurred after ageing 1·3 years), followed by total testosterone (2·4 years), free oestradiol (4·1 years) and total oestradiol (8·1 years). These hormone changes with age translated into 25·0% and 30·2% of men 70+ years old having low total (which we defined as <10·4 nm) and free (<0·17 nm) testosterone, respectively, and 8·3% and 23·9% having low total (<73·4 pm) and free (<2·2 pm) oestradiol. Using population size projections between the 2000 and 2010 Censuses, we estimated that 8·4 (95% CI 4·7-12·2), 6·2 (3·1-9·2) and 6·0 (3·1-9·0) million men 40+ years old may have low total testosterone, free testosterone and free oestradiol, respectively. The prevalences were only modestly lower in men without prevalent chronic diseases. CONCLUSION: Although no consensus exists for defining low hormone levels in ageing men, a substantial number of US men may have low sex steroid hormone levels, possibly putting them at risk for adverse health consequences and premature death.
BACKGROUND: Physiologic processes during ageing leading to multi-morbidity and diseases that increase risk of premature death may be influenced by ageing-associated changes in endogenous hormone production. OBJECTIVE: To evaluate the decline in sex steroid hormone levels across age and estimate the number of US men 40+ years old who may have low hormone levels. DESIGN: We measured serum testosterone, oestradiol and sex hormone binding globulin by immunoassay in 1351 men 20+ years old in Third National Health and Nutrition Examination Survey. We estimated free hormones by mass action. RESULTS: Free testosterone declined most rapidly with age (a 2% decline in geometric mean concentration occurred after ageing 1·3 years), followed by total testosterone (2·4 years), free oestradiol (4·1 years) and total oestradiol (8·1 years). These hormone changes with age translated into 25·0% and 30·2% of men 70+ years old having low total (which we defined as <10·4 nm) and free (<0·17 nm) testosterone, respectively, and 8·3% and 23·9% having low total (<73·4 pm) and free (<2·2 pm) oestradiol. Using population size projections between the 2000 and 2010 Censuses, we estimated that 8·4 (95% CI 4·7-12·2), 6·2 (3·1-9·2) and 6·0 (3·1-9·0) million men 40+ years old may have low total testosterone, free testosterone and free oestradiol, respectively. The prevalences were only modestly lower in men without prevalent chronic diseases. CONCLUSION: Although no consensus exists for defining low hormone levels in ageing men, a substantial number of US men may have low sex steroid hormone levels, possibly putting them at risk for adverse health consequences and premature death.
Authors: Sabina Rinaldi; Annabelle Geay; Henri Déchaud; Carine Biessy; Anne Zeleniuch-Jacquotte; Arslan Akhmedkhanov; Roy E Shore; Elio Riboli; Paolo Toniolo; Rudolf Kaaks Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-10 Impact factor: 4.254
Authors: Henry A Feldman; Christopher Longcope; Carol A Derby; Catherine B Johannes; Andre B Araujo; Andrea D Coviello; William J Bremner; John B McKinlay Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: K K Tsilidis; S Rohrmann; K A McGlynn; S J Nyante; D S Lopez; G Bradwin; M Feinleib; C E Joshu; N Kanarek; W G Nelson; E Selvin; E A Platz Journal: Andrology Date: 2013-09-30 Impact factor: 3.842
Authors: Shannon D Sullivan; Mark S Nash; Eshetu Tefera; Emily Tinsley; Marc R Blackman; Suzanne Groah Journal: PM R Date: 2016-11-18 Impact factor: 2.298
Authors: Susan Chadid; John R Barber; William G Nelson; Bora Gurel; M Scott Lucia; Ian M Thompson; Phyllis J Goodman; Frank Z Stanczyk; Howard L Parnes; Scott M Lippman; Angelo M De Marzo; Elizabeth A Platz Journal: Prostate Date: 2020-06-07 Impact factor: 4.104
Authors: Li Tang; Mary E Platek; Song Yao; Cathee Till; Phyllis J Goodman; Catherine M Tangen; Yue Wu; Elizabeth A Platz; Marian L Neuhouser; Frank Z Stanczyk; Juergen K V Reichardt; Regina M Santella; Ann Hsing; William D Figg; Scott M Lippman; Ian M Thompson; Christine B Ambrosone Journal: Carcinogenesis Date: 2018-02-09 Impact factor: 4.944
Authors: Stefania I Papatheodorou; Sabine Rohrmann; David S Lopez; Gary Bradwin; Corinne E Joshu; Norma Kanarek; William G Nelson; Nader Rifai; Elizabeth A Platz; Konstantinos K Tsilidis Journal: Cancer Causes Control Date: 2014-01-07 Impact factor: 2.506
Authors: Eric S Orwoll; Jodi Lapidus; Patty Y Wang; Liesbeth Vandenput; Andrew Hoffman; Howard A Fink; Gail A Laughlin; Maria Nethander; Östen Ljunggren; Andreas Kindmark; Mattias Lorentzon; Magnus K Karlsson; Dan Mellström; Anthony Kwok; Sundeep Khosla; Timothy Kwok; Claes Ohlsson Journal: J Bone Miner Res Date: 2016-11-14 Impact factor: 6.741
Authors: Laurence Slama; Lisa P Jacobson; Xiuhong Li; Frank J Palella; Joseph B Margolick; Lawrence A Kingsley; Dorothy J Wiley; Gilles Pialoux; Adrian S Dobs; Todd T Brown Journal: J Acquir Immune Defic Syndr Date: 2016-01-01 Impact factor: 3.731